DK1129088T3 - Krystallinsk form af (R)-2-[[[3-methyl-4-(2,2,2-trifluorethoxy)-2-pyridin-yl]methyl]sulfinyl]-1H-ben - Google Patents

Krystallinsk form af (R)-2-[[[3-methyl-4-(2,2,2-trifluorethoxy)-2-pyridin-yl]methyl]sulfinyl]-1H-ben

Info

Publication number
DK1129088T3
DK1129088T3 DK00937235T DK00937235T DK1129088T3 DK 1129088 T3 DK1129088 T3 DK 1129088T3 DK 00937235 T DK00937235 T DK 00937235T DK 00937235 T DK00937235 T DK 00937235T DK 1129088 T3 DK1129088 T3 DK 1129088T3
Authority
DK
Denmark
Prior art keywords
methyl
trifluoroethoxy
sulfinyl
pyridin
bone
Prior art date
Application number
DK00937235T
Other languages
Danish (da)
English (en)
Inventor
Isao Aoki
Akira Fujishima
Keiji Kamiyama
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15924444&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1129088(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of DK1129088T3 publication Critical patent/DK1129088T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK00937235T 1999-06-17 2000-06-15 Krystallinsk form af (R)-2-[[[3-methyl-4-(2,2,2-trifluorethoxy)-2-pyridin-yl]methyl]sulfinyl]-1H-ben DK1129088T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP17150999 1999-06-17
PCT/JP2000/003880 WO2000078745A2 (en) 1999-06-17 2000-06-15 Crystalline form of (r)-2-[[[3-methyl- 4- (2,2,2,- trifluoroethoxy) -2- pyridinyl] methyl] sulfinyl] -1h-benzimidazole

Publications (1)

Publication Number Publication Date
DK1129088T3 true DK1129088T3 (da) 2008-06-09

Family

ID=15924444

Family Applications (2)

Application Number Title Priority Date Filing Date
DK08151945.6T DK1977751T3 (da) 1999-06-17 2000-06-15 Amorf (R)-2-[[[3-methyl-4-(2,2,2-trifluorethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazol som middel mod ulcus
DK00937235T DK1129088T3 (da) 1999-06-17 2000-06-15 Krystallinsk form af (R)-2-[[[3-methyl-4-(2,2,2-trifluorethoxy)-2-pyridin-yl]methyl]sulfinyl]-1H-ben

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK08151945.6T DK1977751T3 (da) 1999-06-17 2000-06-15 Amorf (R)-2-[[[3-methyl-4-(2,2,2-trifluorethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazol som middel mod ulcus

Country Status (26)

Country Link
US (11) US6462058B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (3) EP1129088B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (3) KR100514204B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1150186C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (5) AR031069A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE391126T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU778820B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE2014C017I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BRPI0011674B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2375201C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (2) CY1110384T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE60038481T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (2) DK1977751T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (2) ES2300265T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU229067B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (2) IL145996A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA01012642A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY125399A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO321168B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ515702A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL201068B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (2) PT1977751E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI1129088T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (2) TWI275587B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (2) WO2004083200A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200108331B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US20040224989A1 (en) * 1999-01-29 2004-11-11 Barberich Timothy J. S-lansoprazole compositions and methods
TWI275587B (en) 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
US6608092B1 (en) * 1999-06-30 2003-08-19 Takeda Chemical Industries, Ltd. Crystals of benzimidazole compounds
WO2001083473A1 (fr) 2000-04-28 2001-11-08 Takeda Chemical Industries, Ltd. Procede de production d'un derive de sulfoxide optiquement actif
EP2281821B1 (en) * 2000-05-15 2014-10-22 Takeda Pharmaceutical Company Limited Process for producing a crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole
CA2775616C (en) * 2000-08-04 2013-09-17 Takeda Pharmaceutical Company Limited Salts of benzimidazole compound and application thereof
KR100939948B1 (ko) * 2000-12-01 2010-02-04 다케다 야쿠힌 고교 가부시키가이샤 (ｒ)- 또는 (ｓ)-란소프라졸의 결정
DK2258351T3 (da) 2001-10-17 2013-08-26 Takeda Pharmaceutical Granula indeholdende lansoprazol i stor mængde
KR100467100B1 (ko) * 2002-03-20 2005-01-24 일양약품주식회사 2-[(4-메톡시-3-메틸)-2-피리디닐]메틸설피닐-5-(1Ｈ-피롤-1-릴)-1Ｈ-벤즈이미다졸 또는 이의 Ｎа염을 함유하는주사제의 제조방법
KR20040093187A (ko) * 2002-03-27 2004-11-04 테바 파마슈티컬 인더스트리즈 리미티드 란소프라졸 다형 및 그것의 제조 방법
CA2771725C (en) 2002-10-16 2015-08-18 Takeda Pharmaceutical Company Limited Solid preparation comprising a non-toxic base and a proton pump inhibitor
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
CN100364987C (zh) 2003-03-24 2008-01-30 卫材R&D管理有限公司 亚砜衍生物或其盐的非定形态的制备方法
WO2004113249A2 (en) * 2003-06-20 2004-12-29 Ch Chemicals (Pty) Ltd Polyurethane-based cementitious liner
EP1648416A4 (en) * 2003-07-18 2012-03-28 Santarus Inc PHARMACEUTICAL FORMULATIONS FOR INHIBITING THE ACIDIC ACIDIFICATION AND MANUFACTURING AND USE METHOD
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2005007117A2 (en) * 2003-07-18 2005-01-27 Santarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
US20050249806A1 (en) * 2004-02-10 2005-11-10 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory drug
CA2561700A1 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AU2005264864B2 (en) 2004-06-16 2011-08-11 Takeda Pharmaceutical Company Limited Multiple PPI dosage form
EP2264025B1 (en) 2004-09-13 2013-11-06 Takeda Pharmaceutical Company Limited Method for producing lansoprazole
WO2006090845A1 (ja) 2005-02-25 2006-08-31 Takeda Pharmaceutical Company Limited 顆粒の製造方法
ES2259269B1 (es) 2005-03-03 2007-11-01 Esteve Quimica, S.A. Procedimiento para la preparacion de derivados de 2-(2-piridilmetilsulfinil)-bencimidazol opticamente activos.
EP1934201A1 (en) * 2005-10-06 2008-06-25 Auspex Pharmaceuticals Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
ZA200805646B (en) 2005-12-28 2009-12-30 Takeda Pharmaceutical Controlled release solid preparation
KR100758600B1 (ko) 2006-01-05 2007-09-13 주식회사 대웅제약 란소프라졸 결정형 ａ의 제조방법
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
WO2008068767A2 (en) * 2006-12-07 2008-06-12 Hetero Drugs Limited A novel crystalline form of lansoprazole
WO2008081891A1 (ja) 2006-12-28 2008-07-10 Takeda Pharmaceutical Company Limited 口腔内崩壊性固形製剤
WO2009049160A1 (en) * 2007-10-12 2009-04-16 Takeda Pharmaceuticals North America Methods of treating gastrointestinal disorders independent of the intake of food
NZ585944A (en) * 2007-12-18 2011-11-25 Watson Pharma Private Ltd A process for preparation of stable amorphous R-(+)-lansoprazole
CA2738458A1 (en) * 2007-12-31 2009-07-16 Takeda Pharmaceutical Company Limited Crystalline solvated forms of (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole
ES2638463T3 (es) 2008-03-10 2017-10-20 Takeda Pharmaceutical Company Limited Cristal de compuesto de bencimidazol
NZ588407A (en) * 2008-03-11 2012-07-27 Takeda Pharmaceutical Orally-disintegrating solid preparation
US20110028518A1 (en) * 2008-03-18 2011-02-03 Dr. Reddy's Laboratories Ltd. Dexlansoprazole process and polymorphs
US20090263475A1 (en) * 2008-04-21 2009-10-22 Nagaraju Manne Dexlansoprazole compositions
AU2009336561A1 (en) 2008-05-14 2010-07-15 Watson Pharma Private Limited Stable R-(+)-lansoprazole amine salt and a process for preparing the same
KR20110042334A (ko) * 2008-07-28 2011-04-26 다케다 야쿠힌 고교 가부시키가이샤 약학 조성물
WO2010039885A2 (en) * 2008-09-30 2010-04-08 Teva Pharmaceutical Industries Ltd. Crystalline forms of dexlansoprazole
IT1391758B1 (it) * 2008-11-11 2012-01-27 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo amorfo
WO2010056059A2 (en) * 2008-11-14 2010-05-20 Hanmi Pharm. Co., Ltd. Novel crystalline dexlansoprazole and pharmaceutical composition comprising same
IT1391776B1 (it) * 2008-11-18 2012-01-27 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo
IT1392813B1 (it) * 2009-02-06 2012-03-23 Dipharma Francis Srl Forme cristalline di dexlansoprazolo
US20110009637A1 (en) * 2009-02-10 2011-01-13 Dario Braga Crystals of Dexlansoprazole
WO2011004387A2 (en) * 2009-06-18 2011-01-13 Matrix Laboratories Ltd Process for the preparation of dexlansoprazole polymorphic forms
IT1395118B1 (it) * 2009-07-29 2012-09-05 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo cristallino
WO2011060262A1 (en) 2009-11-12 2011-05-19 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
CN102108076B (zh) * 2009-12-23 2014-07-23 江苏豪森医药集团有限公司 制备无定形右兰索拉唑的方法
AU2011210328A1 (en) 2010-01-29 2012-08-16 Ranbaxy Laboratories Limited Process for the preparation of crystalline forms of dexlansoprazole
US20110189271A1 (en) * 2010-02-02 2011-08-04 Vishal Lad Pharmaceutical formulations of acid-labile drugs
US9085556B2 (en) 2010-03-31 2015-07-21 Ranbaxy Laboraotories Limited Salts of dexlansoprazole and their preparation
US8853411B2 (en) 2010-03-31 2014-10-07 Ranbaxy Laboratories Limited Process for the preparation of dexlansoprazole
EP2384745A3 (en) 2010-05-05 2012-01-18 Sanovel Ilac Sanayi ve Ticaret A.S. Modified release pharmaceutical compositions of dexlansoprazole
EP2384746A3 (en) 2010-05-05 2012-03-07 Sanovel Ilac Sanayi ve Ticaret A.S. Dual release oral tablet compositions of dexlansoprazole
EP2384747A3 (en) 2010-05-05 2012-01-18 Sanovel Ilac Sanayi ve Ticaret A.S. Oral Tablet Compositions Of Dexlansoprazole
US20130216617A1 (en) 2010-06-29 2013-08-22 Cadila Healthcare Limited Pharmaceutical compositions of (r)-lansoprazole
CA2819460C (en) 2010-12-03 2017-08-01 Takeda Pharmaceutical Company Limited Orally disintegrating tablet
SG10201602311XA (en) 2010-12-27 2016-04-28 Takeda Pharmaceutical Orally disintegrating tablet
EP2663306A4 (en) * 2011-01-12 2014-01-01 Hetero Research Foundation POLYMORPHS OF DEXLANSOPRAZOLE SALTS
WO2012104805A1 (en) 2011-02-01 2012-08-09 Ranbaxy Laboratories Limited Process for the preparation of dexlansoprazole
WO2012111024A1 (en) 2011-02-18 2012-08-23 Suven Nishtaa Pharma Pvt Ltd Pharmaceutical compositions of dexlansoprazole
CA2840309A1 (en) * 2011-06-21 2012-12-27 Ranbaxy Laboratories Limited Process for the preparation of dexlansoprazole
CN102875530A (zh) * 2011-07-15 2013-01-16 上海睿智化学研究有限公司 一种(r)-兰索拉唑叔丁胺盐及其晶型和制备方法
CN102875532B (zh) * 2011-07-15 2015-05-13 上海睿智化学研究有限公司 一种(r)-兰索拉唑异丙胺盐及其晶型和制备方法
CN102875531B (zh) * 2011-07-15 2015-08-19 上海睿智化学研究有限公司 一种(r)-兰索拉唑无水晶型及其制备方法
CN102234265B (zh) * 2011-08-08 2013-11-20 天津市汉康医药生物技术有限公司 兰索拉唑化合物
CA2857457C (en) 2011-11-30 2018-05-01 Takeda Pharmaceutical Company Limited Dry coated tablet
KR20140113667A (ko) 2011-12-16 2014-09-24 아토픽스 테라퓨릭스 리미티드 호산구성 식도염의 치료를 위한 ｃｒｔｈ2 길항제 및 양성자 펌프 저해제의 조합
WO2013140120A1 (en) 2012-03-22 2013-09-26 Cipla Limited Glycerol solvate forms of (r) - 2 - [ [ [3 -methyl -4 (2,2, 2 - trifluoroethoxy) pyridin- 2 - yl] methyl] sulphinyl] - 1h - ben zimidazole
WO2013179194A1 (en) 2012-05-31 2013-12-05 Ranbaxy Laboratories Limited Process for the preparation of crystalline dexlansoprazole
CN103709139B (zh) * 2012-10-09 2016-12-21 上海汇伦生命科技有限公司 无水右兰索拉唑的制备方法
CN104177333A (zh) * 2013-05-24 2014-12-03 四川海思科制药有限公司 一种理化性质稳定的(r)-2-[[[3-甲基-4-(2,2,2-三氟乙氧基)-2-吡啶基]甲基]亚磺酰基]-1h-苯并咪唑
CN104650035A (zh) * 2013-11-25 2015-05-27 天津市汉康医药生物技术有限公司 右兰索拉唑倍半水合物化合物
CN103664889B (zh) * 2013-12-19 2014-11-19 悦康药业集团有限公司 一种兰索拉唑化合物
WO2015155281A1 (en) 2014-04-11 2015-10-15 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical combinations of dabigatran and proton pump inhibitors
WO2015155307A1 (en) 2014-04-11 2015-10-15 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical combinations of rivaroxaban and proton pump inhibitors
CN104844576B (zh) * 2015-04-28 2017-03-08 山东罗欣药业集团股份有限公司 一种兰索拉唑或右旋兰索拉唑晶型化合物及其制备方法
CN104829594A (zh) * 2015-05-15 2015-08-12 苗怡文 一种治疗胃溃疡的药物兰索拉唑化合物
CN105017218A (zh) * 2015-07-01 2015-11-04 合肥安德生制药有限公司 一种右兰索拉唑晶型及其制备方法
CN104958276A (zh) * 2015-07-30 2015-10-07 青岛蓝盛洋医药生物科技有限责任公司 一种治疗胃溃疡的药物兰索拉唑组合物胶囊
CN104997738A (zh) * 2015-08-10 2015-10-28 青岛蓝盛洋医药生物科技有限责任公司 一种治疗胃病的药物兰索拉唑组合物干混悬剂
CN105399728B (zh) * 2015-12-20 2017-11-28 寿光富康制药有限公司 一种适用于工业化生产的右兰索拉唑的处理方法
CN108164507A (zh) * 2016-12-07 2018-06-15 天津药物研究院有限公司 一种右兰索拉唑单晶及其制备方法和用途
TR201701461A2 (tr) 2017-01-31 2018-08-27 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dekslansoprazolün Enterik Kaplı Farmasötik Kompozisyonları
CN106866630B (zh) * 2017-04-01 2018-08-07 上海华源医药科技发展有限公司 一种右兰索拉唑的制备方法
CN107011329A (zh) * 2017-05-05 2017-08-04 广州大光制药有限公司 兰索拉唑一水合物晶型及其结晶制备方法
CN108794450B (zh) * 2018-07-24 2022-08-19 浙江恒康药业股份有限公司 制备无定型右旋兰索拉唑的方法
EP4598528A1 (en) 2022-10-04 2025-08-13 Arsenil Zabirnyk Inhibition of aortic valve calcification

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
DK171989B1 (da) 1987-08-04 1997-09-08 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler
DE4035455A1 (de) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
GB9423968D0 (en) 1994-11-28 1995-01-11 Astra Ab Resolution
HRP960232A2 (en) 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
US5840737A (en) * 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6043263A (en) 1996-11-12 2000-03-28 Byk Gulden Lomberg Chemische Fabrik Gmbh (2,3-dihydrobenzofuranyl)-thiazoles as phosphodiesterase inhibitors
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
WO1998022118A1 (en) * 1996-11-22 1998-05-28 The Procter & Gamble Company Compositions for the treatment of gastrointestinal disorders containing bismuth and nsaid
SE510666C2 (sv) 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
EP1056456A4 (en) 1998-01-30 2006-10-25 Sepracor Inc R-LANSOPRAZOL COMPOSITIONS AND TREATMENTS THEREFOR
EP1056457A4 (en) 1998-01-30 2006-10-25 Sepracor Inc S-LANSOPRAZOLE COMPOSITIONS AND METHODS OF USE
AU3596199A (en) * 1998-05-06 1999-11-23 Kobenhavns Universitet Treatment of celiac disease
TWI275587B (en) * 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
JP3283252B2 (ja) * 1999-06-17 2002-05-20 武田薬品工業株式会社 ベンズイミダゾール化合物の結晶
US6608092B1 (en) * 1999-06-30 2003-08-19 Takeda Chemical Industries, Ltd. Crystals of benzimidazole compounds
CN1117747C (zh) * 2000-06-19 2003-08-13 中国科学院成都有机化学研究所 光学纯兰索拉唑的制备方法
CA2771725C (en) * 2002-10-16 2015-08-18 Takeda Pharmaceutical Company Limited Solid preparation comprising a non-toxic base and a proton pump inhibitor
CN100364987C (zh) * 2003-03-24 2008-01-30 卫材R&D管理有限公司 亚砜衍生物或其盐的非定形态的制备方法
WO2006069159A2 (en) * 2004-12-20 2006-06-29 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions comprising amorphous benzimidazole compounds
WO2006067599A2 (en) * 2004-12-23 2006-06-29 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
US20060210637A1 (en) * 2005-03-17 2006-09-21 Qpharma, Llc Stable tablet dosage forms of proton pump inhibitors
NZ585944A (en) * 2007-12-18 2011-11-25 Watson Pharma Private Ltd A process for preparation of stable amorphous R-(+)-lansoprazole

Also Published As

Publication number Publication date
PL352193A1 (en) 2003-08-11
AR079473A2 (es) 2012-01-25
US20150025115A1 (en) 2015-01-22
SI1129088T1 (sl) 2008-08-31
CY1110384T1 (el) 2015-04-29
US20080132547A1 (en) 2008-06-05
EP2343289A1 (en) 2011-07-13
KR100407847B1 (ko) 2003-12-01
PT1129088E (pt) 2008-05-05
KR20010052467A (ko) 2001-06-25
US20100222391A1 (en) 2010-09-02
KR100537029B1 (ko) 2005-12-16
KR20030068592A (ko) 2003-08-21
US20040048898A1 (en) 2004-03-11
NZ515702A (en) 2003-07-25
US8030333B2 (en) 2011-10-04
US8552198B2 (en) 2013-10-08
HUP0201659A2 (hu) 2002-11-28
HK1123985A1 (en) 2009-07-03
BRPI0011674B8 (pt) 2021-05-25
US8884019B2 (en) 2014-11-11
DE60038481D1 (de) 2008-05-15
HU229067B1 (en) 2013-07-29
AR103295A2 (es) 2017-05-03
DE60038481T2 (de) 2009-04-09
US9145389B2 (en) 2015-09-29
ES2426985T3 (es) 2013-10-28
PT1977751E (pt) 2013-08-01
MY125399A (en) 2006-07-31
DK1977751T3 (da) 2013-09-02
EP1129088B1 (en) 2008-04-02
NO20016087D0 (no) 2001-12-13
HK1038227A1 (en) 2002-03-08
US20140012006A1 (en) 2014-01-09
WO2000078745A3 (en) 2001-07-05
BR0011674A (pt) 2002-03-19
US20050228026A1 (en) 2005-10-13
CA2375201C (en) 2010-02-09
AR093609A2 (es) 2015-06-10
IL145996A0 (en) 2002-07-25
US20090163553A1 (en) 2009-06-25
EP1977751A1 (en) 2008-10-08
NO20016087L (no) 2001-12-13
HUP0201659A3 (en) 2003-11-28
KR100514204B1 (ko) 2005-09-13
AU5247800A (en) 2001-01-09
CA2375201A1 (en) 2000-12-28
KR20010071354A (ko) 2001-07-28
WO2004083200A1 (en) 2004-09-30
ES2300265T3 (es) 2008-06-16
ATE391126T1 (de) 2008-04-15
US20120316344A1 (en) 2012-12-13
IL145996A (en) 2008-07-08
CY1114485T1 (el) 2017-01-25
CN1355798A (zh) 2002-06-26
PL201068B1 (pl) 2009-03-31
US6462058B1 (en) 2002-10-08
BE2014C017I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2019-05-21
TWI275587B (en) 2007-03-11
AR100473A2 (es) 2016-10-12
TWI289557B (en) 2007-11-11
US6939971B2 (en) 2005-09-06
AU778820B2 (en) 2004-12-23
US7339064B2 (en) 2008-03-04
US7569697B2 (en) 2009-08-04
EP1977751B1 (en) 2013-07-24
US7737282B2 (en) 2010-06-15
CN1150186C (zh) 2004-05-19
US20030045724A1 (en) 2003-03-06
EP1129088A2 (en) 2001-09-05
WO2000078745A2 (en) 2000-12-28
BRPI0011674B1 (pt) 2017-05-30
NO321168B1 (no) 2006-03-27
US6664276B2 (en) 2003-12-16
AR031069A1 (es) 2003-09-10
MXPA01012642A (es) 2002-07-22
ZA200108331B (en) 2002-10-10
US20110319450A1 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
DK1129088T3 (da) Krystallinsk form af (R)-2-[[[3-methyl-4-(2,2,2-trifluorethoxy)-2-pyridin-yl]methyl]sulfinyl]-1H-ben
DK1149090T3 (da) Ny krystallinsk form af kaliumsalt af (S)-omeprazol
NO20026125D0 (no) Tetrahydropyridin- eller piperidin-heterocykliske derivater
DK0991641T3 (da) Krystallinsk form af omeprazol-natriumsalt
DK1216239T3 (da) Antagonister af piperazin-derivater AS 5-HT1B
DK1284268T3 (da) Fremstilling af en polymorf form af et thiazolidindionderivat
DK1272489T3 (da) Fremgangsmåde til præparation af cabergolins krystallinske form I
ZA989999B (en) New process for the preparation of 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)1H-benzimidazole
DK1254118T3 (da) Substituerede 1,2,3,4-tetrahudroquinolin-2-carboxylsyrederivater
IS6215A (is) Að mestu leyti kristallað form af melagatrani
DK1158963T3 (da) Sammensætninger af betahistin med kontrolleret frigivelse
ATE315025T1 (de) Ethansulfonyl-piperidin-derivate
NO20042980L (no) 3,4-dihydro-1H-isokinolin-2-yl-derivater
IS5821A (is) Kristalluð form af ósanetant
NO20006350D0 (no) Derivater av 3-(2-okso-[1,3']bipyrrolidinyl-3-ylidenmetyl)- cephemer
DK1294694T3 (da) Fremgangsmåde til fremstilling af quinolinderivater
PT1020132E (pt) Aba de puxar destacavel
NO20004583D0 (no) Krystallinsk form av paroxetine
NO20042946L (no) Piperidin-2,6-dioner som er heterocyklisk substituert i posisjon 3
KR100463031B1 (ko) 5-메톡시-2-[3,5-디메틸-4-메톡시피리딜메틸)설피닐]-1h-벤즈이미다졸의신규제조방법
DE60008950D1 (de) Keramikzusammensetzung
DK1191025T3 (da) Krystaller af lansoprazol
DK1104415T3 (da) Fremgangsmåde til fremstilling af 1,3-oxathiolan-nukleosider
DK1079860T3 (da) Nicotin-immunogen
DK1296955T3 (da) Fremgangsmåde til fremstilling af 1,8-naphthalimid